Radiolabelled peptides in diagnosis and therapy: An introduction

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 39, Issue SUPPL.1, 2012, Pages

  Al Nahhas, Adil ^a,c   Fanti, Stefano ^b  

^a IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; ARGINYLGLYCYLASPARTIC ACID; ASTATINE 211; COPPER 64; DOTA NOC GA 68; DOTA RGD GA 68; DOTA TATE GA 68; DOTA TATE LU 177; DOTA TOC GA 68; DOTA TOC Y 90; DOTA VAP PEG P1 GA 68; DOTAVAP P1 GA 68; FLUORINE 18; GALLIUM 68; INDIUM 111; IODINE 123; LUTETIUM 177; NODAGA RGD GA 68; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE; RADIOISOTOPE; SOMATOSTATIN RECEPTOR; TECHNETIUM 99M; TETRAXETAN; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1; YTTRIUM 90; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ANGIOGENESIS; BINDING AFFINITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DOSIMETRY; DRUG HALF LIFE; HUMAN; ISOTOPE LABELING; LIGAND BINDING; METASTASIS; NEUROENDOCRINE TUMOR; NONHUMAN; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIATION EXPOSURE; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; EDITORIAL; METHODOLOGY; NEOPLASM; SCINTISCANNING;

HUMANS; ISOTOPE LABELING; NEOPLASMS; PEPTIDES; RADIONUCLIDE IMAGING; RADIOPHARMACEUTICALS;

EID: 84878458335     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-012-2064-5     Document Type: Review

References (12)

1. Koopmans KP, Glaudemans AW. Rationale for the use of radiolabelled peptides in diagnosis and therapy. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2038-z
2. Fani M, Maecke HR. Radiopharmaceutical development of radiolabelled peptides. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2001-z
3. Decristoforo C, Pickett RD, Verbruggen A. Feasibility and availability of 68Ga-labelled peptides. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 1988-5
4. Pepe G, Moncayo R, Bombardieri E, Chiti A. Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2019-2
5. Ambrosini V, Campana D, Tomassetti P, Fanti S. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1989-4
6. Naji M, AL-Nahhas A. 68Ga-labelled peptides in the management of neuroectodermal tumours. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 1990-y
7. Roivainen A, Jalkanen S, Nanni C. Gallium-labelled peptides for imaging of inflammation. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-1987-6
8. Laverman P, Sosabowski JK, Boerman OC, Oyen WJ. Radiolabelled peptides for oncological diagnosis. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011- 2014-7
9. Bodei L, Cremonesi M, Grana CM, Chinol M, Baio SM, Severi S, et al. Yttrium-labelled peptides for therapy of NET. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2002-y
10. Kam BL, Teunissen JJ, Krenning EP, de Herder WW, Khan S, van Vliet EI, et al. Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2039-y
11. Bomanji JB, Papathanasiou ND. 111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2013-8
12. Gaertner FC, Kessler H, Wester H.-J, Schwaiger M, Beer AJ. Radiolabelled RGD peptides for imaging and therapy. Eur J Nucl Med Mol Imaging. doi: 10.1007/s00259-011-2028-1